newsfilter
← Latest News
GlobeNewswire·

Outlook Therapeutics Reports Financial Results for Fiscal Year 2021 and Provides Corporate Update

Positive clinical data reported for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) in 2021 from multiple clinical trials, including statistically significant top-line efficacy and safety data from pivotal Phase 3 NORSE TWO trial for wet age-related macular d